G D Marijn Veerman
Overview
Explore the profile of G D Marijn Veerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Meerburg J, Veerman G, Aliberti S, Tiddens H
Respir Med
. 2020 Aug;
170:105954.
PMID: 32843159
Background: Bronchiectasis is an irreversible dilatation of the airways caused by inflammation and infection. To diagnose bronchiectasis in clinical care and to use bronchiectasis as outcome parameter in clinical trials,...
22.
Veerman G, Hussaarts K, Peric R, Oomen-de Hoop E, Landa K, van der Leest C, et al.
Clin Pharmacokinet
. 2020 Jun;
60(1):69-77.
PMID: 32557346
Introduction: Erlotinib's gastrointestinal solubility and absorption are decreased by proton pump inhibitors (PPIs). Since erlotinib is a lipophilic drug, we hypothesized that concomitant intake with the fatty beverage milk may...
23.
Veerman G, Hussaarts K, Jansman F, Koolen S, van Leeuwen R, Mathijssen R
Lancet Oncol
. 2020 May;
21(5):e265-e279.
PMID: 32359502
During the past two decades, small-molecule kinase inhibitors have proven to be valuable in the treatment of solid and haematological tumours. However, because of their oral administration, the intrapatient and...
24.
Braal C, Veerman G, Peric R, Aerts J, Mathijssen R, Koolen S, et al.
J Pharm Biomed Anal
. 2019 May;
172:175-182.
PMID: 31051406
An LC-MS/MS method was developed and validated to quantify the tyrosine kinase inhibitor erlotinib in human scalp hair, as alternative matrix to monitor long-term erlotinib exposure. Hair samples from 10...
25.
de Man F, Veerman G, Oomen-de Hoop E, Deenen M, Meulendijks D, Mandigers C, et al.
Ther Adv Med Oncol
. 2019 Apr;
11:1758835919838964.
PMID: 31019570
Background: Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative strategies is lacking. Therefore, we analyzed the toxicity and...
26.
Veerman G, Lam M, Mathijssen R, Koolen S, de Bruijn P
J Chromatogr B Analyt Technol Biomed Life Sci
. 2019 Mar;
1113:37-44.
PMID: 30889498
The development and full validation of a sensitive and selective ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) method are described for the simultaneous analysis of afatinib, alectinib, crizotinib and osimertinib in...
27.
Hussaarts K, Veerman G, Jansman F, van Gelder T, Mathijssen R, van Leeuwen R
Ther Adv Med Oncol
. 2019 Jan;
11:1758835918818347.
PMID: 30643582
Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice. Although the oral route of administration offers improved flexibility and convenience...
28.
Dammeijer F, Lievense L, Veerman G, Hoogsteden H, Hegmans J, Arends L, et al.
J Clin Oncol
. 2016 Jul;
34(26):3204-12.
PMID: 27432922
Purpose: Programmed cell death protein-1- checkpoint blockers have recently been approved as second-line treatment for advanced non-small-cell lung cancer (NSCLC). Unfortunately, only a subgroup of patients responds and shows long-term...